Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated May 11, 2026, announces the commencement of the fifth and final tranche of a share buyback programme. The programme was originally announced on February 24, 2025, with a total authorization of up to £2 billion to be implemented through the end of Q2 2026.
Key Financial Metrics
- Total Programme Authorization: Up to £2 billion.
- Shares Repurchased to Date: 114,436,378 Ordinary Shares.
- Aggregate Consideration Paid to Date: Approximately £1.82 billion.
- Final Tranche Value: Up to approximately £0.18 billion.
- Share Price for Final Tranche: 31½ pence per Ordinary Share.
- Expected Completion Date: June 26, 2026.
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current period.
Material Changes
The primary material change is the activation of the final tranche of the buyback programme. The first four tranches, totaling approximately £1.9 billion in authorization (£0.7bn, £0.45bn, £0.3bn, and £0.45bn respectively), have been completed in accordance with their terms. The final tranche of £0.18 billion is now active to complete the full £2 billion programme.
Guidance, Outlook, and Risks
Management Commentary: The purpose of the programme is to return excess capital to shareholders, reduce share capital, and enhance earnings per share. Purchased shares will be held as Treasury shares. Trading decisions for the final tranche are made independently by Citigroup Global Markets Limited within pre-set parameters.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the 2025 Annual Report on Form 20-F and Q1 2026 results. The programme is subject to UK Market Abuse Regulation and FCA regulations. No repurchases will be made in the United States or regarding American Depositary Receipts.
Investor Verification Checklist
- Verify the total number of shares repurchased and the final aggregate cost upon programme completion in June 2026.
- Confirm the impact of the £2 billion buyback on the company's earnings per share (EPS) in subsequent earnings reports.
- Review the 2025 Annual Report on Form 20-F and Q1 2026 results for detailed risk factors and financial performance metrics not included in this filing.
- Monitor the remaining general authority for share repurchases (up to 406,980,539 Ordinary Shares) granted at the 2026 Annual General Meeting.